

Informazione Regolamentata n. 20343-15-2025	Data/Ora Inizio Diffusione 11 Dicembre 2025 08:15:01	Euronext Growth Milan
---	---	-----------------------

Societa' : OTOFARMA

Utenza - referente : OTOFARMAESTN01 - Anna Incarnato  
Bartolomucci

Tipologia : REGEM

Data/Ora Ricezione : 11 Dicembre 2025 08:15:01

Data/Ora Inizio Diffusione : 11 Dicembre 2025 08:15:01

Oggetto : OTOFARMA AWARDED "BEST IPO 2025" AT  
THE ASSONEXT AWARDS

*Testo del comunicato*

Vedi allegato



Press release

## OTOFARMA AWARDED “BEST IPO 2025” AT THE ASSONEXT AWARDS

***The prestigious award recognizes the strength of the company’s equity story, which has succeeded in attracting and maintaining the interest of both Italian and international markets.***

Naples, 11 December 2025 – – Otofarma Group – with over 30 years of experience in the hearing care sector and a leading manufacturer of hearing aids distributed primarily through the pharmacy channel – announces that it has been awarded the prestigious **Best IPO 2025** during the Assonext Awards 2025 ceremony, held yesterday evening at Palazzo Mezzanotte. The award was accepted by **Giovanna Incarnato Bartolomucci** and **Anna Incarnato Bartolomucci**, respectively CEO and IR & Corporate Legal Affairs Director of the Group.

The Best IPO 2025 award is closely tied to the perception and trust demonstrated by stock market participants—evaluated from the listing process onward—regarding the Company’s solidity and growth prospects. The recognition takes into account the **funds raised** during the IPO—an undisputed success for Otofarma—the **stock’s performance on its first trading day** (+13%), the Company’s commitment to **sound governance principles**—reflected in the significant presence of independent and female board members—and, above all, the robustness of its **equity story**, defined by the scalability of its business model and its historically proven profitability.

The award granted to Otofarma therefore represents a further confirmation of the strategic decisions made by the management, which enabled the Group’s debut on the EGM market in August, less than one year after initiating the listing process. The IPO marked a **fundamental strategic milestone**, aimed at raising resources that will allow the Company to enhance its investments in **technological innovation and patient services**, expand its footprint through its **pharmacy network**, and **strengthen its market leadership**.

Being named Best IPO 2025 further validates the strength and profitability of the Company’s equity story and its **pioneering business model**—a unique presence in the market capable of meeting the needs of hearing-impaired patients through a widespread network of affiliated pharmacies and an efficient and streamlined production process that enables the customization of each device.

The award also highlights Otofarma’s long-standing commitment to **innovation**, aimed at improving the lives of people with hearing difficulties by offering solutions that support an active professional and social life without limitations—such as the new products set to enter the market next year. Leveraging Artificial Intelligence algorithms, the new devices will automatically and instantly recalibrate sound processing according to the patient’s lifestyle, addressing a therapeutic gap that has yet to be effectively managed. These innovations will also play a key role in strengthening **partnerships with pharmacies**, which are increasingly embracing and promoting Otofarma’s business model.

The listing has also ushered in a new and fundamental phase for the Group: the transition to the stock market has accelerated a **cultural and organizational evolution** across the Company, driving growth in a transparent, sustainable, and shared manner. It has fostered a new collective awareness of the visibility and weight of corporate achievements, as well as of the role, responsibility, and commitment required both individually and collectively.



*“The Best IPO 2025 award,” commented Anna Incarnato Bartolomucci, “is above all a recognition of an equity story built on a true ‘alliance’ with our shareholders, partners, and employees, based on the shared understanding of objectives and growth strategy—first presented during the IPO and reaffirmed during our recent Road Show in Milan.”*

Giovanna Incarnato Bartolomucci added: *“This recognition reflects the commitment, vision, and passion that have always guided our Company. Today, we look forward with greater awareness and strength, proud of having built a business model that is transparent, distinctive, and a driver of future growth and sustainability.”*

\*\*\*

The Company uses the EMARKET SDIR and STORAGE circuit, managed by Teleborsa, for the dissemination of Regulated Information. This system is authorized by [CONSOB](#) by resolutions No. 22517 and No. 22518 of November 23, 2022, pursuant to Article 113-ter, paragraph 4, letter a, of Legislative Decree No. 58/1998. For further information on the greenshoe option, please refer to the admission document available in the Investor Relations section of the website [www.otofarmaspa.com](http://www.otofarmaspa.com).

#### Identification Codes

Alphanumeric Code: OTO

ISIN for Ordinary Shares: IT0005663361

\*\*\*

#### About Otofarma SpA

*Otofarma Group is a leader in the design, production, and distribution of customized hearing aids through pharmacies. Its reputation is built on technological innovation and continuous research, offering advanced audiological solutions at a guaranteed democratic price, with the goal of making hearing care more accessible and widespread.*

*Pioneering in telemedicine, Otofarma was the first company in Europe to introduce specialist tele-audiology services in pharmacies, today available under Otofarma brand in more 4,000 partner pharmacies, making access to diagnosis and personalized devices easier.*

*Founded by Gennaro Bartolomucci, now Chairman, and led by CEO Giovanna Incarnato Bartolomucci, the company holds six patents for its proprietary software and instruments. Its devices and services are distributed exclusively through partner pharmacies, ensuring a controlled, quality-focused business model.*

#### For more information:

##### Otofarma S.p.A.- Investor relations

Anna Incarnato Bartolomucci

E-mail: [investor.relations@otofarma.it](mailto:investor.relations@otofarma.it)

mob: +39 347 0506780

##### Alantra – Euronext Growth Advisor

E-mail: [ega@alantra.com](mailto:ega@alantra.com)

mob: +39 334 6267242

##### SEC Newgate – Media Relations

+39 02 624 999 1

Michele Bon – [michele.bon@secnewgate.it](mailto:michele.bon@secnewgate.it) – +39 338 693 3868

Francesca Brambilla – [francesca.brambilla@secnewgate.it](mailto:francesca.brambilla@secnewgate.it) – +39 338 627 2146

